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Background: EGFR-targeted therapy is an attractive option for head and neck squamous cell carcinoma patients.
We have recently reported the use of EGFR inhibitors as an adjunct treatment to enhance HLA-DR expression in
tumor cells to improve cancer immunotherapy. Nevertheless, we observed that EGFR inhibitors resulted in decreased
anti-tumor responses, regardless of upregulation of HLA-DR expression on the tumor cell. In this study, we specifically
investigated the mechanisms by which EGFR inhibition modulated anti-tumor responses.
Methods: An EGFR inhibitor erlotinib was used to assess the modulation of anti-tumor responses by tumor
antigen-specific helper T cells. We then examined whether administration of the EGFR inhibitor altered tumor
cytokine profiles and expression of immune-related molecules on tumor cells.
Results: Despite the augmented HLA-DR expression on a gingival cancer cell line by EGFR inhibition, anti-tumor
responses of EGFR reactive helper T cell clones against tumor cells were decreased. EGFR inhibition did not change
the expression of CD80, CD86, or PD-L1 on the tumor cells. Conversely, production of transforming growth factor beta
(TGF-β) and prostaglandin E2 was increased by EGFR inhibition, indicating that these immunosuppressive molecules
were involved in diminishing tumor recognition by T cells. Significantly, attenuation of HTL responses against tumors
after EGFR inhibition was reversed by the addition of anti-TGF-β antibody or COX2 inhibitors.
Conclusions: Targeting TGF-β and prostaglandin E2 may allow for improved outcomes for cancer patients treated with
combination immunotherapy and EGFR inhibitors.
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Immunotherapy is a promising strategy for increasing sur-
vival in cancer patients, and has been an active area research
for decades. Amongst various types of immunotherapy, the
induction of anti-tumor CD8 cytotoxic T lymphocyte (CTL)
responses via vaccination with peptide epitopes has been
widely applied in the clinical setting [1]. Unfortunately, CTL
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unless otherwise stated.for treating cancer, possibly due to a combination of sub-
optimal immune responses and to tumor-derived immune
suppressive activities.
Many strategies have been applied to enhance antigen-
specific anti-tumor immunity, including the activation of
natural killer (NK) cells, conversion of macrophage pheno-
type, and immune-modulating adjuvants [2-4]. Among
these, the blockade of immunological checkpoints such as
CTLA-4/B7 and PD-1/PD-L1 is quite advanced and has
yielded promising clinical results [5]. It is predicted that
the use of non-specific anti-cancer immunity targeted ther-
apy may be a valuable complement to tumor antigen-
specific immunity against cancer.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in anti-cancer immunity by promoting the induction
and survival of CD8+ CTLs. In addition, in some in-
stances HTLs can also exhibit direct anti-tumor cytotoxic
activity. In view of this, our laboratories have focused on
the identification of peptide epitopes capable of inducing
cytotoxic HTL responses against tumor cells that express
surface MHC class II molecules [6]. Recently, long-
peptide vaccines have been used with the purpose of indu-
cing both CTL and HTL anti-tumor responses, with
promising clinical results [7].
The disruption of the antigen-processing machinery is
one of the mechanisms utilized by tumor cells to evade
T cell recognition. To overcome this problem, we and
other groups have recently proposed that the increase of
MHC class II protein expression on tumor cells obtained
with EGFR inhibitors could be implemented to enhance
HTL anti-tumor responses [8,9]. Although EGFR inhibi-
tors have been widely used to treat many types of cancer,
the usefulness of these therapies is limited due to the ap-
pearance of drug resistance [10,11]. Immune regulatory
cytokine TGF-β has been reported to mediate the resist-
ance to EGFR inhibition, however, direct activity of EGFR
mediated TGF-β production from tumor toward antitu-
mor immune cells has remained largely unknown [12].
In this study, we discovered that EGFR inhibition al-
though increased MHC-II expression, paradoxically it at-
tenuated HTL responses against some head and neck
squamous cell carcinoma (HNSCC) cells. We observed
that secretion of TGF-β and PGE2 by the HNSCC cells
was increased following EGFR inhibition, despite a lack
of evident changes in immune costimulatory molecules
or EGFR expression in tumor cells. Inhibition of TGF-β
or COX-2 salvaged HTL responses against EGFR inhibitor-
treated HNSCC cells, suggesting that these pathways
played a crucial role in immunosuppression. Taken to-
gether, our results demonstrate that in some cases, EGFR
inhibitors may skew the immune response towards T cell
suppression, and that concomitant blockade of EGFR and
TGF-β/COX-2 may be promising combinatorial thera-




HNSCC cell lines HSC-3, HSC-4 (tongue SCC, DR1/4)
and Sa-3 (gingival SCC, DR9/10) were provided by the
RIKEN Bio-Resource Center (Tsukuba, Japan). CA9-22
(gingival SCC) and HPC-92Y (hypopharyngeal SCC)
were kindly provided by Dr. Yasuharu Nishimura (Dep.
of Immunogenetics, Kumamoto University, Kumamoto,
Japan) and Dr. Syunsuke Yanoma (Yokohama Tsurugamine
Hospital, Yokohama, Japan), respectively. SAS (tongue
SCC), Calu-1 (non-small cell lung carcinoma) and5637 (bladder cancer) were purchased from American
Type Culture Collection (Manassas, VA). All cell lines
were maintained in RPMI 1640 (nacalai tesque, Kyoto,
Japan) supplemented with 10% fetal bovine serum.
Western blotting
Cells (1 × 106) were washed in phosphate-buffered saline
(PBS) and lysed in NuPAGE sample buffer (Invitrogen, CA).
The lysates were subjected to electrophoresis (NuPAGE bis-
Tris SDS-PAGE gel (Invitrogen, CA)) and transferred to
Immobilon-P membrane (Millipore, Bedford, MA). The
membrane was soaked in blocking buffer (PBS containing
5% non-fat dry milk and 0.01% Tween 20, 1 h) at
room temperature. Blots were then incubated with
polyclonal rabbit anti-human EGFR (sc-03; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA), polyclonal rabbit
anti-human phospho-EGFR (Tyr1068; Cell Signaling
Technology, Denver, MA), polyclonal rabbit anti-human
heat shock protein 70 (HSP70) (Enzo Life Sciences, Inc.,
Farmingdale, NY), or monoclonal rat anti-human heat
shock protein 90 (HSP90) (Enzo Life Sciences) diluted
1:500 in blocking buffer, or anti β-actin mAb (Santa Cruz
Biotechnology) diluted 1:1,000 in blocking buffer, for 18 h
at 4°C. The membrane was incubated with HRP-labeled
sheep anti rabbit or anti mouse IgG after washing, and
made visible by an enhanced chemiluminescence (ECL)
system (Amersham, Buckinghamshire, UK).
Synthetic peptides
The synthetic peptide used throughout this study was
EGFR875–889 (KVPIKWMALESILHR) [8]. The peptide
epitope was synthesized by solid-phase organic chem-
istry and purified by high performance liquid chromatog-
raphy. The purity (80%<) and identification of peptides
were assessed by high performance liquid chromatography
and mass spectrometry, respectively.
Measurement of antigen-specific responses with antigen
reactive CD4+ T-cell clones
Antigen-specific CD4+ T cells were induced by peptide
stimulation of fresh peripheral blood mononuclear cells
(PBMCs) from healthy volunteers [13]. EGFR875–889-reactive
CD4+ T cell clones T8 (from an HLA-DR 9/12 individual)
and M8 (from an HLA-DR 9/13 individual) were used.
These clones were restricted by HLA-DR53 as recently
described [8]. CD4+ T-cells (3 × 104 cells/well) were mixed
in 96 well culture plates with irradiated antigen-presenting
cells (APCs) that consisted of either autologous PBMCs
(1 × 105 cells/well) or tumor cell lines (3 × 104 cells/well).
HNSCC cells were pretreated with interferon gamma
(IFN-γ, 500 U/ml, 48 h) to increase HLA-DR expression
prior to the assay. To examine the role of EGFR inhibitor
in augmenting the MHC class II molecules expression,
HNSCC cells were preincubated with reversible EGFR
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Chemicals, Houston, TX), for 2 h at 37°C before addition
of IFN-γ. DMSO was used as control. Tumor cells were
washed twice with PBS to eliminate the residual chemicals.
Expression of the HLA-DR and B7-H1 on tumors was
evaluated by flow cytometry using anti HLA-DR mAb con-
jugated with fluorescein isothiocyanate (FITC), anti B7-H1
mAb (eBioscience, Minneapolis, MN), and anti-mouse im-
munoglobulin conjugated with FITC (Dako Denmark A/S,
Glostrup, Denmark). Detection of surface CD80 and CD86
was carried out using unconjugated mouse anti-human
CD80 IgG1 (MAB104,Immunotech, Marseille, France) and
unconjugated mouse anti-human CD86 IgG2b (HA5.2B7,
Immunotech, Marseille, France) followed by FITC-
conjugated rabbit anti-mouse immunoglobulin anti-
body (1:100; Dako, Denmark A/S, Glostrup, Denmark).
Anti-TGF-β Ab (10 μg/ml; Abcam, Tokyo, Japan), cele-
coxib (10 μM; Sigma-Aldrich Japan, Tokyo, Japan), recom-
binant PGE2 (1 μM; Sigma-Aldrich Japan) or supernatant
of tumor culture were added to the co-culture medium for
functional studies. CD4+ T-cells culture supernatants were
collected after 48 h to quantify antigen-induced IL-4, IL-10
or IFN-γ production using ELISA assays (BD Pharmingen,
San Diego, CA). Culture supernatants from erlotinib-treated
tumor cells were collected for quantification of TGF-β and
PGE2 using ELISA kits (TGF-β eBioscience, San Diego, CA;
PGE2: R&D Systems, Inc., Minneapolis, MN).
Statistical analysis
All data are presented as mean ± standard deviation. In all
experiments, group differences were analyzed by using the
two-tailed Student’s t test and p <0.05 was considered as
statistically significant.Figure 1 Alteration of HLA-DR expression in HNSCCs by EGFR inhibito
examined by flow cytometry. HNSCC cells were treated with IFN-γ (50U/
isotype control antibody, Green graph: anti HLA-DR antibody. (B) Mean
means of triplicate determinations, bars: SD. Results are representative of at leResults
Downregulation of EGFR-reactive CD4+ T cell responses
against HNSCC cells pretreated with EGFR inhibitor
Recently, we reported that the newly identified CD4+ T cell
peptide epitope EGFR875–889 functions as a promiscuous
MHC-II HTL epitope that can elicit effective antitumor re-
sponses towards tumors expressing various HER family
member proteins that have a high degree of homology in
the peptide sequence [8]. In these studies we proposed that
EGFR inhibitors might be effective adjuncts for cancer im-
munotherapy because these drugs increased MHC-II
expression levels on tumor cells, which should enhance
CD4+ T cell recognition. As shown in Figure 1A, the ex-
pression of HLA-DR in the SCC cell lines HSC-4 and Sa-3
was increased following erlotinib treatment. Moreover, the
effect of erlotinib was more prominent (~2-fold higher) on
the Sa-3 cells as compared to HSC-4 (Figure 1B). Because
Th1 response has been reported as a key subset in antitu-
mor T cell responses [14], we used Th1 cytokine IFN-γ as
a read out for HTL reactions toward tumor or peptide
stimulation. As predicted, erlotinib pretreatment enhanced
HTL responses against HSC-4 (Figure 2A). In contrast, er-
lotinib decreased the T cell response to Sa-3 cells despite
the dramatic upregulation of HLA-DR (Figure 2B). These
results indicate that in addition to increasing MHC-II
levels on tumor cells, EGFR inhibitors can regulate T cell
recognition through other mechanisms.
Treatment of HNSCC cells with EGFR inhibitor
downregulates the expression of HSP90 but not EGFR
Efficient HTL responses are mediated by the inter-
action of T cell receptors with MHC-II molecules
presenting the cognate peptide antigen on tumorr. (A) HLA-DR expression of HNSCC cell lines HSC-4 and Sa-3 was
ml) alone or with IFN-γ and erlotinib (1 μM) for 48 h. Purple graph:
fluorescence intensity (MFI) of HLA-DR expression was shown. Columns:
ast two separate experiments. *p < 0.05.
Figure 2 EGFR inhibitor attenuated anti-tumor responses of EGFR875–889-reactive CD4
+ T cell clones against Sa-3. (A) (B) EGFR875–889-reactive
CD4+ T cell clones T8 (DR53-restricted) and M8 (DR53-restricted) were tested for their capacity to recognize antigen directly on EGFR-positive, HLA-DR
matched HNSCC cell line HSC-4 or Sa-3 by IFN-γ production. Tumor cells were pretreated 48 h with or without erlotinib (1 μM). DMSO was used as
negative control. Columns without bars had SD of <10% of mean values. Results are representative of three separate experiments. *p < 0.05.
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the tumor cell sand the antigen-processing machinery
will determine the production of the cognate peptide
antigen. Thus, we evaluated the effect of EGFR in-
hibition on the levels of EGFR protein in tumor cells.
As shown in Figure 3A, unlike phosphorylated EGFR,
the total EGFR protein levels in HSC-4 and Sa-3
cells remained unchanged after erlotinib treatment.
Meantime, we examined the expression levels of
HSP70 and HSP90, which are known to be important
components for antigen processing [15]. Expression of
HSP70 remained unchanged by EGFR inhibition. However,
HSP90 expression was decreased by erlotinib treatment, al-
though the degree of downregulation was more prominent
in HSC-4 than the Sa-3 cells (Figure 3A), which does not
correlate with the observed results in HTL recognition of
the tumor cells.
Expression of costimulatory molecules on tumor cells is
unaffected by EGFR inhibitor treatment
B7 family ligands are costimulatory molecules that
regulate immune responses [16]. To further assess
the mechanisms of the immune inhibition by erloti-
nib treated Sa-3 cells, we measured the surface ex-
pression of stimulatory B7 family members CD80
and CD86. After 48-h erlotinib treatment, the ex-
pression levels of both CD80 and CD86 on Sa-3 cellsremained unchanged (Figure 3B). The expression
level of the inhibitory molecule PD-L1 (B7-H1) on
the Sa-3 tumor cells also showed no significant
change after erlotinib treatment (Figure 3B). These
data suggests that the effect of EGFR inhibition on
the immune regulatory activity of Sa-3 was not medi-
ated by changes in the expression of costimulatory/
inhibitory B7 molecules on tumor cells.EGFR inhibitor promotes PGE2 and TGF-β secretion from
Sa-3 tumor cells
Soluble factors such as cytokines and prostaglandins
can regulate the immune function of T cells [17,18]. In-
deed, as shown in Figure 4 the addition of PGE2 de-
creases the HTL response to EGFR875–889-loaded
PBMCs as antigen-presenting cells, suggesting that the
immuno-inhibitory effect on T cells could be partly due
to the effects of PGE2. Thus, we evaluated whether the
negative effects of erlotinib in the T cell recognition of
Sa-3 were mediated by immunosuppressive factors pro-
duced by the tumor cells as the result of EGFR inhib-
ition. Indeed, secretion levels of PGE2 and TGF-β by
Sa-3 but not by HSC-4 were increased following erloti-
nib treatment (Figure 5). On the other hand, IL-4 and
IL-10 levels were below levels of detection regardless of
erlotinib treatment (data not shown).
Figure 3 EGFR, HSP and costimulatory molecules expression on HNSCC cells. (A) HNSCC tumor cells were incubated with erlotinib (1 μM)
for 48 h and the expression of EGFR, pEGFR, HSP70, and HSP90 was examined by western blot. (B) CD80, CD86, and PD-L1 expression on HNSCC
cell lines HSC-4 and Sa-3 was examined by flow cytometry. HNSCC cells were treated with IFN-γ (50 U/ml) alone (red line) or IFN-γ and erlotinib
(1 μM; blue line) for 48 h.
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EGFR inhibitor
So far only few reports have reported the relationship
between EGFR targeted therapy and TGF-β expres-
sion [12], the direct relationship between EGFR tar-
geted therapy, TGF-β expression and antitumor T
cells remains unproved. Contrary to our results,
EGFR TKI was reported to decrease PGE2 production
from lung cancer cells [19]. To evaluate whether in-
creased TGF-β and PGE2 production by EGFR inhibi-
tor is detected in a broad range of epithelial tumors
or just restricted to the SCC cell line Sa-3, we evalu-
ated these cytokine production in several tumor cell
lines pretreated with EGFR TKI. As shown in Figure 5,
TGF-β production following EGFR inhibition was in-
creased in two additional cell lines (Calu1 and 5637).
However, TGF-β production was decreased or un-
altered in other cell lines. PGE2 production was seen
in four to eight cell lines but EGFR TKI treatment
was enable to increase production only in Sa-3. Theseresults indicate that EGFR targeted therapy can alter
TGF-β production differently depending on the can-
cer cell line studied.
Immune regulatory effect of erlotinib is mediated by
TGF-β and PGE2
The data presented above suggested that secretion of
PGE2 and TGF-β by the Sa-3 tumor cell after treatment
with erlotinib might be the cause of the decreased CD4+
T cell responses. To confirm this possibility, HTL
responses against Sa-3 cells treated with erlotinib were
measured following the addition of COX-2 inhibitor or
neutralizing anti-TGF-β antibody. The results showed in
Figure 6A show that the COX-2 inhibitor effectively re-
stored CD4+ T cell function against Sa-3 pretreated with
erlotinib. Similarly, anti-TGF-β antibody was sufficient to
overcome the immune suppressive effects of Sa-3 treated
with erlotinib (Figure 6B). Because HTLs used in this
study could not directly recognize Calu1 and 5637,
HTL responses to autologous PBMCs with EGFR peptide
Figure 5 EGFR inhibitor modulated PGE2 and TGF-β production from
and CA9-22, non-small cell lung cancer cell line Calu-1 and bladder cancer
TGF-β. Tumor cells were pretreated 48 h with or without erlotinib (1 μM
representative of three separate experiments. *p < 0.05.
Figure 4 Responses of EGFR875–889-reactive CD4
+ T cell clones to
EGFR875–889 peptide were attenuated by PGE2. EGFR875–889-reactive
CD4+ T cell clone M8 was tested for its capacity to recognize
EGFR875–889 peptide by using autologous PBMCs as APCs with or
without PGE2 (1 μM) by quantification of IFN-γ production. Columns
without bars had SD of <10% of mean values. Results are representative
of three separate experiments. *p < 0.05.
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nib were examined to strengthen the observation that
EGFR inhibition mediated immune suppression through
TGF-β. As shown in Figure 7, supernatant of Calu-1 and
5637 treated with erlotinib significantly reduced the HTL
response and this reduction was recovered by adding anti
TGF-β antibody to culture. These results demonstrate that
TGF-β is at least partly responsible for EGFR inhibitor-
mediated tumor immune evasion, and that targeting the
TGF-β pathway and/or COX-2 pathway might be powerful
strategies for restoration of immunosuppression caused
by blockade of EGFR.
Discussion
We recently reported the capacity of EGFR inhibitors to
augment HLA-DR surface expression on tumor cells [8].
After HLA-DR up-regulation, most EGFR inhibitor-
treated HNSCC cell lines became more susceptible to
antitumor responses mediated by CD4+ T cells. However,
in the present study, we report that despite HLA-DR
augmentation on the tumor cells, in some instances EGFR
inhibition suppressed antitumor T cell responses by indu-
cing the production of TGF-β and PGE2. Suppression ofHNSCC cell lines. HNSCC cell lines HSC-4, Sa-3, SAS, HSC-3, HPC-92Y
cell line 5637 were tested for their capacity to produce PGE2 and
). Columns without bars had SD of <10% of mean values. Results are
Figure 6 Inhibition of COX-2 or TGF-β recovered immune-suppression by HNSCC cell line Sa-3 pretreated with erlotinib. EGFR875–889-
reactive CD4+ T cell clone M8 was tested for its capacity to recognize erlotinib (1 μM)-pretreated Sa-3 with or without (A) celecoxib (10 μM) and
(B) anti-TGF-β antibody (10 μg) by quantification of IFN-γ production. Columns without bars had SD of <10% of mean values. Results are representative
of three separate experiments. *p < 0.05.
Figure 7 Supernatant of tumor pretreated with EGFR inhibitor modulated T cell responses toward peptide stimulation. EGFR875–889-reactive
CD4+ T cell clone T8 and M8 were tested for their capacity to recognize 3 μg/ml peptide pulsed-autologous PBMC with or without supernatant of
Calu-1 or 5637 tumor cells culture and anti-TGF-β antibody (10 μg) by measuring of IFN-γ production. Columns without bars had SD of <10% of mean
values. Results are representative of three separate experiments. *p < 0.05.
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TGF-β antibody or COX-2 inhibitor, supporting the ration-
ale for inhibition of TGF-β and COX-2 pathways to over-
come potential immunosuppressive effects due to EGFR
inhibition. Since EGFR inhibitor plays a detrimental role in
tumor proliferation, it would be assumed that the de-
creased number of tumor cell could affect the immune re-
action because of the lesser antigen. Pretreatment with
erlotinib definitely decreased tumor cell survival in our
study (data not shown), however, we did not conclude this
antigen reduction is the main reason of attenuated T cell
responses against tumor cells. Firstly, we washed erlotinib-
pretreated tumor cells before cocultured with T cells to re-
move residual erlotinib. Second, we found that anti TGF-β
antibody clearly recovered the function of T cells. Lastly,
supernatant of tumors treated with erlotinib attenuated the
T cell responses suggesting that humoral factors from
tumor cells affect the T cell responses in our assay. Thus,
TGF-β might at least play a harmful role in antitumor T
cell responses against tumor treated with EGFR inhibitor.
In this study, we found the high variability between
cell lines of expressing TGF-β and PGE2 after EGFR in-
hibition. Because substantial heterogeneity within tumors
has been elucidated [20], it is difficult to determine a sin-
gle factor that induces diversity of tumors. For example,
tumor cell uses an alternative signaling such as HER-3
when EGFR signaling is inhibited [21], suggesting that
tumor cells can transform their function to adapt to the
surrounding microenvironment. Thus, it is speculated that
TGF-β or PGE2 producing tumor cells are established
from tumors that survive under immune surveillance and
further studies elucidating the biomarker to distinguish
the TGF-β or PGE2 producing and non-producing tumors
with EGFR inhibition may help us to better treat the pa-
tients with anti TGF-β antibody or COX inhibitor.
Experimental evidences that the tumor microenviron-
ment plays a significant role in resistance of EGFR inhibitor
have been reported [12,22-25]. EGFR inhibition induces
tumor cells to the mesenchymal phenotype, which cell type
show resistant to EGFR inhibitor, via cytokines such as IL-6
and TGF-β [22]. Both exogenous IL-6 and TGF-β induced
EGFR inhibitor resistance [12,23,24] and endogenous TGF-
β was produced from EGFR inhibitor resistant tumor cells
[22]. Strikingly, TGF-β receptor inhibitor abrogated motility
of erlotinib-resistant tumor cells suggesting that cytokines
might be promising target to overcome EGFR inhibitor
resistance [25]. The TGF-β pathway is known as an im-
portant immune suppressor pathway affecting tumor
microenvironment. TGF-β can regulate both the innate
and acquired immune systems by inducing regulatory
CD4+/FoxP3+ T cells, which represent on of the main
barriers to antigen-specific antitumor immunity, and by
skewing NK T cells or macrophages to regulatory pheno-
types [3,4,26]. TGF-β functions not only as an immuneregulator, but also as an oncogenesis promoter by inducing
epithelial-to-mesenchymal transition through both Smad-
dependent and independent pathways [27] or transitioning
constitutive cells to a tumor-associated phenotype that fa-
cilitates tumor progression [28]. The present study revealed
that TGF-β production or reduction by EGFR inhibition is
depended on individual tumors. Further studies will be
needed to determine whether TGF-β can function as a bio-
marker to assess the effectiveness of EGFR targeted therapy
with and without concurrent immunotherapy.
Prostaglandins and leukotrienes are produced by the
COX pathway and function as potent immune regulators.
Both the tumor and surrounding stroma are capable of
producing PGE2 [29], which can increase regulatory T cell
activity [18]. Furthermore, PGE2 induces myeloid-derived
suppressor cells, which inhibit effector T cells [30]. Accu-
mulating evidence suggests that the application of COX
inhibitors may be useful for cancer treatment both in
colorectal cancer and in HNSCC [31]. In this study, we
showed that EGFR inhibition augmented PGE2 produc-
tion by Sa-3 tumor cell, and that COX-2 inhibitor could
restore the suppression of antigen-specific CD4+ T cell re-
sponses. Thus, the COX-2/PGE2 pathway is partially re-
sponsible for immunosuppressive effects of tumor cells
through EGFR blockade. While reduction of PGE2 by er-
lotinib has been reported [19], we could not detect PGE2
reduction by EGFR inhibition suggesting that the fluctu-
ation of PGE2 production by EGFR blockade is affected
by cancer heterogeneity. Recently, COX-2 inhibitor with
erlotinib has been reported to inhibit the proliferation of
head and neck squamous cell carcinoma in patients [32].
Although we could show the increase of PGE2 production
by EGFR inhibition only in tumor cell Sa-3, we believe our
result may partly elucidate the mechanism of positive ef-
fects of COX-2 inhibitor with erlotinib.
Conclusions
We have identified TGF-β and PGE2 as immune suppres-
sors that can disrupt EGFR inhibition-mediated immune
activation. These results may facilitate strategy for targeting
TGF-β and COX-2 with EGFR inhibition to overcome
tumor immune evasion and reveal a novel aspect of signal
targeted therapy in altering immune regulated cytokines.
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